Dolutegravir (DTG) plus emtricitabine (FTC) is a safe, effective option for long-term HIV management, according to results of a study published in Open Forum Infectious Diseases.
The findings come from a cohort study (ClinicalTrials.gov Identifier: NCT03160105) of adult patients with HIV infection who were enrolled across 7 Swiss HIV Cohort Study sites. All study patients were on European AIDS Clinical Society-approved 3-drug combination antiretroviral therapy (ART) and had been virologically suppressed for at least 24 weeks at enrollment. Researchers randomly assigned patients 1:1 to either switch to DTG/FTC or continue their current combination ART regimen, as well as to patient-centered monitoring or standard routine monitoring. The objective of the study was to determine whether DTG/FTC was noninferior to combination ART for maintaining viral suppression through 144 weeks.
Read the full story at Infectious Disease Advisor.
Source : Infectious Disease Advisor
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.